47 related articles for article (PubMed ID: 18280336)
1. Subcutaneous efalizumab is not effective in the treatment of alopecia areata.
Price VH; Hordinsky MK; Olsen EA; Roberts JL; Siegfried EC; Rafal ES; Korman NJ; Altrabulsi B; Leung HM; Garovoy MR; Caro I; Whiting DA
J Am Acad Dermatol; 2008 Mar; 58(3):395-402. PubMed ID: 18280336
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
4. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
Strober BE; Menon K; McMichael A; Hordinsky M; Krueger G; Panko J; Siu K; Lustgarten JL; Ross EK; Shapiro J
Arch Dermatol; 2009 Nov; 145(11):1262-6. PubMed ID: 19917955
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment.
Park H; Kim JE; Choi JW; Kim DY; Jang YH; Lee Y; Jeon J; Shin HT; Kim MS; Shin JW; Cho SB; Lew BL; Choi GS
Ann Dermatol; 2023 Jun; 35(3):205-216. PubMed ID: 37290954
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases.
Kinoshita-Ise M; Fukuyama M; Ohyama M
J Clin Med; 2023 May; 12(9):. PubMed ID: 37176700
[TBL] [Abstract][Full Text] [Related]
7. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E; Renert-Yuval Y; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Garcet S; Pavel AB; Lebwohl MG; Krueger JG
Allergy; 2022 Mar; 77(3):897-906. PubMed ID: 34460948
[TBL] [Abstract][Full Text] [Related]
8. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
Zhou C; Li X; Wang C; Zhang J
Clin Rev Allergy Immunol; 2021 Dec; 61(3):403-423. PubMed ID: 34403083
[TBL] [Abstract][Full Text] [Related]
9. Oral Pulse Betamethasone, Methotrexate, and Combination Therapy to Treat Severe Alopecia Areata: A Randomized, Double-blind, Placebo-controlled, Clinical Trial.
Asilian A; Fatemi F; Ganjei Z; Siadat AH; Mohaghegh F; Siavash M
Iran J Pharm Res; 2021; 20(1):267-273. PubMed ID: 34400956
[TBL] [Abstract][Full Text] [Related]
10. Alopecia Areata: An Autoimmune Disease of Multiple Players.
Suchonwanit P; Kositkuljorn C; Pomsoong C
Immunotargets Ther; 2021; 10():299-312. PubMed ID: 34350136
[TBL] [Abstract][Full Text] [Related]
11. Immunology of alopecia areata.
Żeberkiewicz M; Rudnicka L; Malejczyk J
Cent Eur J Immunol; 2020; 45(3):325-333. PubMed ID: 33437185
[TBL] [Abstract][Full Text] [Related]
12. Objective outcome measures: Collecting meaningful data on alopecia areata.
Olsen EA; Roberts J; Sperling L; Tosti A; Shapiro J; McMichael A; Bergfeld W; Callender V; Mirmirani P; Washenik K; Whiting D; Cotsarelis G; Hordinsky M
J Am Acad Dermatol; 2018 Sep; 79(3):470-478.e3. PubMed ID: 29128463
[TBL] [Abstract][Full Text] [Related]
13. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
Trüeb RM; Dias MFRG
Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
[TBL] [Abstract][Full Text] [Related]
14. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.
Renert-Yuval Y; Guttman-Yassky E
Adv Ther; 2017 Jul; 34(7):1594-1609. PubMed ID: 28646393
[TBL] [Abstract][Full Text] [Related]
15. Alopecia areata.
Pratt CH; King LE; Messenger AG; Christiano AM; Sundberg JP
Nat Rev Dis Primers; 2017 Mar; 3():17011. PubMed ID: 28300084
[TBL] [Abstract][Full Text] [Related]
16. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
17. The continuing evolution of targeted therapy for inflammatory skin disease.
Schlapbach C; Navarini AA
Semin Immunopathol; 2016 Jan; 38(1):123-33. PubMed ID: 26423993
[TBL] [Abstract][Full Text] [Related]
18. An overview of alopecias.
Qi J; Garza LA
Cold Spring Harb Perspect Med; 2014 Mar; 4(3):. PubMed ID: 24591533
[TBL] [Abstract][Full Text] [Related]
19. Biologics in dermatology.
Chandler D; Bewley A
Pharmaceuticals (Basel); 2013 Apr; 6(4):557-78. PubMed ID: 24276125
[TBL] [Abstract][Full Text] [Related]
20. What causes alopecia areata?
McElwee KJ; Gilhar A; Tobin DJ; Ramot Y; Sundberg JP; Nakamura M; Bertolini M; Inui S; Tokura Y; King LE; Duque-Estrada B; Tosti A; Keren A; Itami S; Shoenfeld Y; Zlotogorski A; Paus R
Exp Dermatol; 2013 Sep; 22(9):609-26. PubMed ID: 23947678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
